Keryx: This Biotech Is No Zombie

Veteran biotech investors see more than their fair share of zombies. Not the flesh-eating kind popularized on the shows like The Walking Dead, but former highflying stocks banished to obscurity after a big drug failure only to rise again without valid reason. But every once in a while, you see a company come back stronger than before it was sent into the penny-stock wilderness.

In this video, Motley Fool health-care analyst discusses how Keryx Pharmaceuticals' impressive 76% pop and how key drug Zerenex's successful trial has reinvented Keryx into more than just a zombie biotech.

The Motley Fool's chief investment officer has selected his No. 1 stock for the next year. Find out which stock it is in our brand-new free report: "The Motley Fool's Top Stock for 2013." Grab a free copy for a limited time. Just click here to access the report and find out the name of this under-the-radar company.



Read/Post Comments (1) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

DocumentId: 2220388, ~/Articles/ArticleHandler.aspx, 8/1/2014 5:05:51 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...